Cetera Trust Company N.A Buys Shares of 746 Boston Scientific Co. (NYSE:BSX)

Cetera Trust Company N.A bought a new stake in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 746 shares of the medical equipment provider’s stock, valued at approximately $43,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its position in shares of Boston Scientific by 5.6% during the 3rd quarter. Victory Capital Management Inc. now owns 518,047 shares of the medical equipment provider’s stock valued at $27,353,000 after acquiring an additional 27,620 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in shares of Boston Scientific during the 4th quarter valued at about $5,116,000. Glenmede Trust Co. NA boosted its position in shares of Boston Scientific by 12.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock valued at $551,000 after acquiring an additional 1,123 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Boston Scientific by 2.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,868,991 shares of the medical equipment provider’s stock valued at $98,683,000 after acquiring an additional 38,249 shares during the last quarter. Finally, HealthInvest Partners AB bought a new stake in shares of Boston Scientific during the 4th quarter valued at about $3,746,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Wells Fargo & Company boosted their target price on Boston Scientific from $70.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. JPMorgan Chase & Co. lifted their price target on Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Evercore ISI lifted their price target on Boston Scientific from $68.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Mizuho raised Boston Scientific from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $65.00 to $80.00 in a research note on Thursday, February 1st. Finally, Citigroup upped their price target on Boston Scientific from $71.00 to $79.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.50.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the sale, the director now directly owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the sale, the director now directly owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Daniel J. Brennan sold 13,662 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,979 shares of company stock worth $3,418,529. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Up 1.0 %

Shares of NYSE:BSX opened at $68.02 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $69.21. The company has a market cap of $99.79 billion, a P/E ratio of 63.57, a PEG ratio of 2.36 and a beta of 0.78. The stock’s fifty day moving average price is $67.31 and its 200-day moving average price is $60.07.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The firm had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same period in the previous year, the business posted $0.45 earnings per share. Sell-side analysts expect that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.